Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment

Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment

Abstract Background Hypoxia is inherent character of most solid malignancies, leading to the failure of chemotherapy, radiotherapy and immunotherapy. Atovaquone, an anti-malaria drug, can alleviate tumor hypoxia by inhibiting mitochondrial complex III activity. The present study exploits atovaquone/...

Full description

Bibliographic Details
Main Authors: Simeng Wang, Xinrui Zhou, Zekun Zeng, Mengjun Sui, Lihong Chen, Chao Feng, Chen Huang, Qi Yang, Meiju Ji, Peng Hou
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Journal of Nanobiotechnology
Subjects:
Hypoxic tumor microenvironment
Atovaquone
Anti-PD-1 therapy
Nano-drugs
Tumor targeting
Online Access:https://doi.org/10.1186/s12951-021-01034-9

Internet

https://doi.org/10.1186/s12951-021-01034-9

Similar Items